Jonathan Havens of Saul Ewing Arnstein & Lehr LLP to talk about what the US FDA’s approval of GW Pharma’s Epidiolex CBD-derived product. Havens described what will happen to Epidiolex now – including a possible rescheduling by the US Drug Enforcement Administration. For more…
Read More
Jonathan Havens of Saul Ewing Arnstein & Lehr LLP to talk about what the US FDA’s approval of GW Pharma’s Epidiolex CBD-derived product. Havens described what will happen to Epidiolex…
More
